No­var­tis rolls out its next big drug at a record-set­ting price of $2.12M — let the gene ther­a­py pric­ing de­bate be­gin

Let the next big de­bate over gene ther­a­py pric­ing be­gin now.

No­var­tis an­nounced mid­day Fri­day that the FDA had stamped its OK on Zol­gens­ma, a ground­break­ing gene ther­a­py for lethal cas­es of spinal mus­cu­lar at­ro­phy that will test the mar­ket’s ac­cep­tance of 7-fig­ure prices.

Af­ter years of dis­cus­sion and de­bate, No­var­tis set the price at $2.12 mil­lion spread out over a 5-year in­stall­ment plan.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER